Biolexis Therapeutics, Inc.

Biolexis Therapeutics, Inc. is a US-based startup founded in 2021 with a focus on accelerating drug discovery in the healthcare and pharmaceutical industries. The company's slogan "Accelerating Drug Discovery" encapsulates its mission to revolutionize the process of discovering and developing novel drugs. Biolexis leverages its proprietary Moleculern™ technology, which involves screening each Moleculern™ fragment against a curated protein target library, resulting in 600K real/empirical data points and scaffold-like compounds that can be used to design new drug candidates.

The latest milestone for Biolexis is the $10.00M Series A investment led by Clarke Capital Group on 29 November 2023. This investment signifies a vote of confidence in the potential of Biolexis and its innovative approach to drug discovery. The company's advanced machine learning and AI-backed platform is set to expedite the development process by mapping hot-spots, computing ligand properties, and building accurate empirical models, ultimately translating into active, safe, and efficacious novel chemical entities (NCEs) for future medicines.

By accelerating drug discovery and development to new therapeutics, shortening the path to the clinic, expediting First-In-Human (FIH) clinical trials, and facilitating the delivery of medicines to patients worldwide, Biolexis is positioned to make a significant impact in the healthcare and pharmaceutical sectors. As a result, the recent Series A investment underscores the potential for Biolexis to emerge as a key player in advancing the future of medicine.